Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Cerebroprotective effects of aminoguanidine in a rodent model of stroke
Kevin M. Cockroft
, Malcolm Meistrell
, Gary A. Zimmerman
, Donald Risucci
, Ona Bloom
, Anthony Cerami
, Kevin J. Tracey
Department of Neurosurgery
Department of Public Health Sciences
Department of Radiology
Penn State Neuroscience Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
90
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Cerebroprotective effects of aminoguanidine in a rodent model of stroke'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Rodent Models of Stroke
100%
Aminoguanidine
100%
Ischemia
50%
Experimental Therapeutics
25%
Common Carotid Artery
25%
Infarct Volume
25%
Drug Delivery
12%
Clinical Trials
12%
Mean Arterial Pressure
12%
Possible Mechanisms
12%
Brain Slice
12%
Lewis Rats
12%
Ketamine
12%
Blood Glucose
12%
Brain Cells
12%
Cerebral Infarction
12%
Partial Pressure of CO2 (pCO2)
12%
Cell Loss
12%
Diabetes Complications
12%
Middle Cerebral Artery
12%
Physiological Variables
12%
Tetrazolium
12%
Temperature Mean
12%
Temporary Occlusion
12%
Arterial pH
12%
Neuroscience
Cerebrovascular Accident
100%
Ischemia
100%
Cerebral Infarction
75%
Common Carotid Artery
50%
Brain Slice
25%
Diabetes Mellitus
25%
Cell Loss
25%
Middle Cerebral Artery
25%
Ketamine
25%
Medicine and Dentistry
Apoplexy
100%
Ischemia
50%
Brain Infarction
37%
Experimental Therapeutic
25%
Infarction
25%
Hemisphere
25%
Common Carotid Artery
25%
Clinical Trial
12%
Mean Arterial Pressure
12%
Ketamine
12%
Brain Cell
12%
Blood Glucose
12%
Cell Loss
12%
Contralateral
12%
Tetrazolium
12%
Complications of Diabetes Mellitus
12%
Brain Slice
12%
Pharmacology, Toxicology and Pharmaceutical Science
Cerebrovascular Accident
100%
Ischemia
50%
Brain Infarction
37%
Infarction
25%
Experimental Therapeutic
25%
Clinical Trial
12%
Lewis Rat
12%
Tetrazolium
12%
Ketamine
12%
Diabetic Complication
12%